Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 12;57(1):62.
doi: 10.3390/medicina57010062.

Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities

Sylvia Annabel Dass  1 , Kim Liu Tan  1 , Rehasri Selva Rajan  1 , Noor Fatmawati Mokhtar  2 , Elis Rosliza Mohd Adzmi  2 , Wan Faiziah Wan Abdul Rahman  3   4 , Tengku Ahmad Damitri Al-Astani Tengku Din  4   5 , Venugopal Balakrishnan  1
Affiliations
Review

Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities

Sylvia Annabel Dass et al. Medicina (Kaunas). .

Abstract

Triple-negative breast cancer (TNBC) is an aggressive breast type of cancer with no expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). It is a highly metastasized, heterogeneous disease that accounts for 10-15% of total breast cancer cases with a poor prognosis and high relapse rate within five years after treatment compared to non-TNBC cases. The diagnostic and subtyping of TNBC tumors are essential to determine the treatment alternatives and establish personalized, targeted medications for every TNBC individual. Currently, TNBC is diagnosed via a two-step procedure of imaging and immunohistochemistry (IHC), which are operator-dependent and potentially time-consuming. Therefore, there is a crucial need for the development of rapid and advanced technologies to enhance the diagnostic efficiency of TNBC. This review discusses the overview of breast cancer with emphasis on TNBC subtypes and the current diagnostic approaches of TNBC along with its challenges. Most importantly, we have presented several promising strategies that can be utilized as future TNBC diagnostic modalities and simultaneously enhance the efficacy of TNBC diagnostic.

Keywords: breast cancer; future diagnosis; triple negative breast cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The intrinsic subtyping of breast cancer based on immunohistochemical profile.
Figure 2
Figure 2
The subtypes of triple negative breast cancer.
Figure 3
Figure 3
Working principles of nanobiosensor. Bioreceptor form biological reaction when bind to sample analyte which caused changes in either current, wavelength, mass, or temperature. The biological response will then be converted to electrical signals via the transducer. Nanomaterials that integrate with transducers is to detect low concentrations of analytes.
Figure 4
Figure 4
Overview of dPCR. Sample is added and combined with qPCR reagent. It is then equally distributed into many sub-volumes (either in microwells, chambers, or droplets) which results in some partitions to contain few targets and some without. Each subdivided portion will undergo amplification. The positive columns will be identified and the target concentrations will be determined via Poisson’s statistics.
See this image and copyright information in PMC

References

    1. Vallejos C.S., Gómez H.L., Cruz W.R., Pinto J.A., Dyer R.R., Velarde R., Suazo J.F., Neciosup S.P., León M., de la Cruz M.A., et al. Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database. Clin. Breast Cancer. 2010;10:294–300. doi: 10.3816/CBC.2010.n.038. - DOI - PubMed
    1. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., Harris L., Hait W., Toppmeyer D. Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast Cancer. J. Clin. Oncol. 2006;24:5652–5657. doi: 10.1200/JCO.2006.06.5664. - DOI - PubMed
    1. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. Clin. Cancer Res. 2004;10:5367. doi: 10.1158/1078-0432.CCR-04-0220. - DOI - PubMed
    1. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. doi: 10.1038/35021093. - DOI - PubMed
    1. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 2001;98:10869–10874. doi: 10.1073/pnas.191367098. - DOI - PMC - PubMed

Substances

LinkOut - more resources